Healthcare provider profile · identity verified

Bradley D Cutting, MD

Family Practice · WAMEGO, KS · NPI 1639214463

Profile state: partd only Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

We did not find matching Open Payments records for this doctor in 2025.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

We did not find matching Open Payments records for this doctor in the selected program year.

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Analysis 1 · Payment-linked products

Products named in Open Payments records

No payment-linked product analysis is available because no matching General Payment records were found for the selected year.

Public prescribing for products named in payments

There is no explicit payment-product set available for a Part D comparison.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

There is no payer-company set available for this comparison.

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Levothyroxine Sodium	Levothyroxine Sodium	240	60
Atorvastatin Calcium	Atorvastatin Calcium	172	58
Lisinopril	Lisinopril	167	53
Simvastatin	Simvastatin	164	44
Metformin Hcl	Metformin Hcl	130	37
Losartan Potassium	Losartan Potassium	123	40
Omeprazole	Omeprazole	116	33
Amlodipine Besylate	Amlodipine Besylate	109	37
Hydrochlorothiazide	Hydrochlorothiazide	99	33
Gabapentin	Gabapentin	92	21
Arexvy	Rsvpref3 Antigen/As01e/Pf	89	89
Tamsulosin Hcl	Tamsulosin Hcl	81	24
Potassium Chloride	Potassium Chloride	78	24
Montelukast Sodium	Montelukast Sodium	74	20
Pantoprazole Sodium	Pantoprazole Sodium	67	24
Metoprolol Succinate	Metoprolol Succinate	61	26
Shingrix	Varicella-Zoster Ge/As01b/Pf	61	46
Furosemide	Furosemide	59	16
Eliquis	Apixaban	57	12
Prednisone	Prednisone	57	43
Duloxetine Hcl	Duloxetine Hcl	54	16
Allopurinol	Allopurinol	48	14
Doxycycline Hyclate	Doxycycline Hyclate	46	39
Glimepiride	Glimepiride	46	suppressed
Meloxicam	Meloxicam	46	18
Xarelto	Rivaroxaban	45	suppressed
Sertraline Hcl	Sertraline Hcl	44	suppressed
Donepezil Hcl	Donepezil Hcl	43	12
Trazodone Hcl	Trazodone Hcl	41	suppressed
Citalopram Hbr	Citalopram Hydrobromide	40	suppressed
Alendronate Sodium	Alendronate Sodium	39	11
Albuterol Sulfate Hfa	Albuterol Sulfate	38	13
Pravastatin Sodium	Pravastatin Sodium	38	12
Clopidogrel	Clopidogrel Bisulfate	37	11
Rosuvastatin Calcium	Rosuvastatin Calcium	37	suppressed
Metoprolol Tartrate	Metoprolol Tartrate	36	12
Tramadol Hcl	Tramadol Hcl	36	14
Escitalopram Oxalate	Escitalopram Oxalate	35	suppressed
Carvedilol	Carvedilol	34	suppressed
Lisinopril-Hydrochlorothiazide	Lisinopril/Hydrochlorothiazide	33	suppressed
Zolpidem Tartrate	Zolpidem Tartrate	33	suppressed
Cyclobenzaprine Hcl	Cyclobenzaprine Hcl	28	12
Hydroxyzine Hcl	Hydroxyzine Hcl	27	12
Ozempic	Semaglutide	27	suppressed
Ezetimibe	Ezetimibe	25	suppressed
Warfarin Sodium	Warfarin Sodium	25	suppressed
Alprazolam	Alprazolam	23	suppressed
Famotidine	Famotidine	23	suppressed
Adacel Tdap	Diph,pertuss(Acell),tet Vac/Pf	21	20
Metformin Hcl Er	Metformin Hcl	21	suppressed
Fluticasone Propionate	Fluticasone Propionate	20	suppressed
Memantine Hcl	Memantine Hcl	20	suppressed
Phenytoin Sodium Extended	Phenytoin Sodium Extended	20	suppressed
Diltiazem 24hr Er	Diltiazem Hcl	19	suppressed
Fluoxetine Hcl	Fluoxetine Hcl	19	suppressed
Azithromycin	Azithromycin	18	15
Clonazepam	Clonazepam	17	suppressed
Paroxetine Hcl	Paroxetine Hcl	17	suppressed
Nitrofurantoin Mono-Macro	Nitrofurantoin Monohyd/M-Cryst	16	13
Triamcinolone Acetonide	Triamcinolone Acetonide	16	14
Bupropion Xl	Bupropion Hcl	15	suppressed
Hydrocodone-Acetaminophen	Hydrocodone/Acetaminophen	15	suppressed
Budesonide-Formoterol Fumarate	Budesonide/Formoterol Fumarate	14	suppressed
Finasteride	Finasteride	14	suppressed
Sulfamethoxazole-Trimethoprim	Sulfamethoxazole/Trimethoprim	14	11
Buspirone Hcl	Buspirone Hcl	13	suppressed
Klor-Con M20	Potassium Chloride	13	suppressed
Lantus Solostar	Insulin Glargine,hum.Rec.Anlog	13	suppressed
Olmesartan Medoxomil	Olmesartan Medoxomil	13	suppressed
Rybelsus	Semaglutide	13	suppressed
Triamterene-Hydrochlorothiazid	Triamterene/Hydrochlorothiazid	12	suppressed
Verapamil Er	Verapamil Hcl	12	suppressed
Atenolol	Atenolol	11	suppressed
Breo Ellipta	Fluticasone/Vilanterol	11	suppressed
Dantrolene Sodium	Dantrolene Sodium	11	suppressed
Felodipine Er	Felodipine	11	suppressed
Pioglitazone Hcl	Pioglitazone Hcl	11	suppressed
Spironolactone	Spironolactone	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	—	—	—	—	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error